- Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin2019 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn's disease: an analysis of two propensity score-matched cohorts2022 | First Faculty of Medicine, Faculty of Physical Education and Sport
